NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced it has been added to the Russell Microcap Index. The addition is effective when the US market opens on June 29, as part of the 2026 Russell indexes reconstitution.
The semi-annual June reconstitution of the Russell US Indexes captures the 4,000 largest US stocks as of April 30, ranked by total market capitalization. Membership in the Russell 3000 Index, which remains in place for half a year beginning 2026, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. The Russell Microcap Index consists of the smallest 1,000 securities in the Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2025, about $12.2 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. Inclusion in the Russell Microcap Index could enhance NeuroOne's visibility among institutional investors and increase demand for its shares as index funds automatically adjust their holdings.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For more information on the Russell Microcap Index and the Russell indexes reconstitution, visit the FTSE Russell website and see the “Russell Reconstitution” section. Additional details about NeuroOne can be found at nmtc1.com.
